Open Orphan Share Discussion Threads

[mjb252] 06/1/2021 16:31

And there you have it!

[realcooltrader] 06/1/2021 16:31

RNS, Invesco has indeed sold a few.

[chica1] 06/1/2021 16:30

Who is selling all these shares?
Could it be Invesco?
Wouldn't they have to do a filing?

[slartybartfaster] 06/1/2021 16:15

Why moderate some for mentioning another company. Are we not here to share information for our mutual benefit. We can choose to ignore it.

[chopsy] 06/1/2021 16:11

Happy to give up a ha'penny from time to time in the interests of consolidation.

[m5] 06/1/2021 16:06

I would love to see this pop blue before close. It is frustrating further progress and the sp, so far, reverses. Generally its been a great day on the markets.

Looking at things we might have a chance of finishing blue, lets see.

[jeanesy] 06/1/2021 15:41

Just seen your reply bobsworth :) Its only going to get worse now we are on lockdown again !!

[marvelman] 06/1/2021 15:23

SMTM/Trader

This is one of the many appealing reasons to hold ORPH. You never know what's round the corner with CF forever looking for further opportunities. Another reason not to trade. Truly, a RNS could come tomorrow on so many irons in the fire and new irons getting ready to go in it.

[lhoskins] 06/1/2021 15:18

Why trade this for a couple of pence when approval for HCS could drop at any time? Not worth the risk.

[sh0wmethemoney] 06/1/2021 15:13

On Trader 3’s find I e had the following thoughts, what u think guys?

Southampton centre 25 miles from Porto Down, so would come under same health authority I assume, is there something in it I wonder if something is happening there to? 🤔

[toyin] 06/1/2021 14:36

Sorry m5, didn't see your reply earlier.

Agree, very poor!

[m5] 06/1/2021 14:04

Are you on a wind up? Take a hint fella.

[m5] 06/1/2021 13:46

I agree. The markets are bent there is no question of that, however these lot will have a bit of information but not the full story, hence chancing their arm on dropping on something bigger.

[qackers] 06/1/2021 13:18

Last few paragraphs from Vox market article referred to by Bobsworth in post 10221

Planned Disposal
When Open Orphan acquired hVIVO in January 2020, hVIVO also came with a number of non-core assets including a 62.6% stake in PrEP Biopharm. However, the new Open Orphan Board and management team are primarily focussed upon cementing its position as a unique CRO and ‘world leader vaccine and antiviral testing using human challenge study models, and therefore earmarked all non-core assets for disposal.

The options for disposal of this unique asset are exciting, numerous and particularly timely given its mode of action. These options could include a trade sale to a Big-Pharma for cash, reverse the asset into the resurgence of listed SPACs and Cash Shells, or even Spin the asset out into a newly listed entity delivering investors dividends in specie of newly formed companies.

In any event, OPRH shareholders would do well to remain on the Shareholder register when this transaction takes place as, whilst the valuation of PrEP Biopharm is currently unknown, with little carrying value on the Open Orphan balance sheet, it should advance the share price accordingly.

[trader_3] 06/1/2021 13:13

Research Nurse Vacancy – NHS University Hospital Southampton

Research Nurse

'This is an exciting opportunity for nurses to be involved at the forefront of research (including Covid-19 vaccine research) at UHS….

….. We currently have vacancies for Band 5 research nurses within both our Covid-19 vaccine and clinical research facility adult research nurse teams. These roles come with the expectation that all the successful candidates will be able to work “face-to-face” with COVID-19 suspected or positive patients. In addition within the adult nursing team there will be opportunities to work on research studies in haematology, neurology, new advanced therapy treatments, early phase vaccine studies including first in human clinical trials and human challenge studies.'

hxxps://www.jobs.nhs.uk/xi/vacancy/916333312

Is something occurring in Southhampton?

[m5] 06/1/2021 13:08

marvelman6 Jan '21 - 12:45 - 10217 of 10221

What they will have access to, probably, is that an RNS is due, not what it contains IMHO. So those buying will have been speculating on maybe a "wearables" deal type rns.

[bobsworth] 06/1/2021 12:59

https://www.voxmarkets.co.uk/articles/open-orphan-renews-contract-with-major-top-3-global-pharmaceutical-client-3084c55/

[bobsworth] 06/1/2021 12:57

True to form it will not long now before we hear from Cathal ! I sense more news again this week as some flip flop in and out for a song. Good start to New Year and in no doubt it will continue.

[jeanesy] 06/1/2021 12:52

Surely it is only a matter of time before this company gets realised for what it is . I keep thinking what i am missing. Great company. If i wasn't overweight already id be buying more at this price !

[marvelman] 06/1/2021 12:45

It does surprise me this morning that those that clearly had access to the RNS information yesterday afternoon were so desperate to have been buying at 27.5 on the back of what is in effect not so material news. Certainly those trading at those levels cannot surely be making worthwhile returns but just as surely will be taking risky gambles. Just not worth the hassle even though this morning I could not even be bothered to change my portfolio spreadsheet to reflect the 27.5 bid when I was almost certain it would settle back again.

[toyin] 06/1/2021 12:22

1gw, would you like to give me circa £9m then?

The Finncap note is wrong.

[1gw] 06/1/2021 12:18

AFAICS the headline cash is "correct" in the finnCap note, just rather confusing.

They have reported negative net debt of -£13.3m, which is the same as positive net cash of £13.3m.

This is the 30th June position reported in the interims, £14.65m of cash & equivalents less £1.32m of borrowings. Although CF has spoken of current higher levels of cash, finnCap presumably feel they need to quote the last balance sheet number as the "current" headline.

In terms of the end-2020 position, they estimate £18.4m net cash (£18.4m gross & no gross debt), which is perhaps a bit out of date (Orph have quoted £20.3m net = £21.5m gross less £1.3m debt as of 27th October, and perhaps higher numbers in presentations after that date).

I agree with the pointlessness comments. I have seen this on other companies as well. It looks to me as though finnCap are trying to put in place a framework of conservative valuation where they only count the parts of the business that are nailed down and leave all the other stuff (even the relatively probable stuff) as largely unquantified upside. I would guess this is as a result of criticism of being over-optimistic about valuations and target prices in the past, but it does seem absurd for a company like ORPH where an expected valuation would likely be so much higher than a "nailed down" valuation because of the high expected value of a number of the business development options under negotiation.